PDF(Pubmed)
Abstract：
UNASSIGNED: Abnormal uterine bleeding (AUB) is a common problem in reproductive age group and perimenopausal age group being responsible for many outpatient visits. Traditional management of AUB consists of giving mefenamic acid, tranexamic acid, or their combination with progestogens or hormonal intrauterine deviced levonorgestrel intrauterine system (LNG-IUS) for severe or nonresponsive cases. The objective of the current study was to study the efficacy and safety of adding diosmin along with tranexamic acid and mefenamic acid in reducing menstrual blood loss in AUB patients.
UNASSIGNED: It was a prospective double-blind randomized controlled trial in which 900 mg of diosmin was given once daily along with 500 mg tranexamic acid and 250 mg mefenamic acid during menstruation (Group I-92 patients), or only tranexamic acid and mefenamic acid during menstruation (Group II-92 patients).
UNASSIGNED: Mean age, parity, body mass index, and socioeconomic status were similar in the two groups. It was 35.68 years versus 36.78 years, 2.2 versus 2.3, 23.68 kg/m2 versus 24.62 kg/m2 respectively. Mean days of bleeding before this treatment were 6.8 versus 6.6 (P = 0.33) and were 3.5 versus 5.2 (P = 0.02) after treatment. There was a significant reduction in both groups as compared to before treatment (P = 0.021 in Group I, 0.027 in Group II) but the reduction was greater in Group I (P = 0.02). The amount of blood loss was 385 ml versus 390 ml (P = 0.7) before treatment which was significantly reduced in both groups to 68 ml versus 112 ml (P = 0.02 in Group I, 0.03 in Group II) with more decrease in Group I than in Group II (P = 0.01). Mean hemoglobin at beginning of the study was 8.4 versus 8.5 g/dl in Group I and Group II (P = 0.02) and significantly increased in both groups posttreatment to 10.9 and 9.8 g/dl in Group I and Group II (P = 0.012 in Group I, 0.011 in Group II) with increase being more in Group I than Group II (P = 0.03). Pictorial blood assessment chart score was 398 versus 406 (P = 0.35) before treatment and decreased significantly to 86.5 and 110.5 (P = 0.001 in Group I, 0.001 in Group II) with more decrease being in Group I than II (P = 0.01). There was significant decrease in dysmenorrhea with both treatments with no difference in the two groups. Various adverse effects such as nausea, vomiting, abdominal pain, diarrhea, constipation, and headache were equal in the two groups.
UNASSIGNED: Both the group\'s diosmin with tranexamic acid and mefenamic acid (Group I) and tranexamic acid and mefenamic acid (Group II) were efficacious in reducing menstrual blood loss, number of menstrual days and dysmenorrhea with effect being more by addition of diosmin. Adverse effects were equal in both the two groups.
UNASSIGNED: It was a prospective double-blind randomized controlled trial in which 900 mg of diosmin was given once daily along with 500 mg tranexamic acid and 250 mg mefenamic acid during menstruation (Group I-92 patients), or only tranexamic acid and mefenamic acid during menstruation (Group II-92 patients).
UNASSIGNED: Mean age, parity, body mass index, and socioeconomic status were similar in the two groups. It was 35.68 years versus 36.78 years, 2.2 versus 2.3, 23.68 kg/m2 versus 24.62 kg/m2 respectively. Mean days of bleeding before this treatment were 6.8 versus 6.6 (P = 0.33) and were 3.5 versus 5.2 (P = 0.02) after treatment. There was a significant reduction in both groups as compared to before treatment (P = 0.021 in Group I, 0.027 in Group II) but the reduction was greater in Group I (P = 0.02). The amount of blood loss was 385 ml versus 390 ml (P = 0.7) before treatment which was significantly reduced in both groups to 68 ml versus 112 ml (P = 0.02 in Group I, 0.03 in Group II) with more decrease in Group I than in Group II (P = 0.01). Mean hemoglobin at beginning of the study was 8.4 versus 8.5 g/dl in Group I and Group II (P = 0.02) and significantly increased in both groups posttreatment to 10.9 and 9.8 g/dl in Group I and Group II (P = 0.012 in Group I, 0.011 in Group II) with increase being more in Group I than Group II (P = 0.03). Pictorial blood assessment chart score was 398 versus 406 (P = 0.35) before treatment and decreased significantly to 86.5 and 110.5 (P = 0.001 in Group I, 0.001 in Group II) with more decrease being in Group I than II (P = 0.01). There was significant decrease in dysmenorrhea with both treatments with no difference in the two groups. Various adverse effects such as nausea, vomiting, abdominal pain, diarrhea, constipation, and headache were equal in the two groups.
UNASSIGNED: Both the group\'s diosmin with tranexamic acid and mefenamic acid (Group I) and tranexamic acid and mefenamic acid (Group II) were efficacious in reducing menstrual blood loss, number of menstrual days and dysmenorrhea with effect being more by addition of diosmin. Adverse effects were equal in both the two groups.
摘要：
■异常子宫出血（AUB）是生育年龄组和围绝经期年龄组的常见问题，是许多门诊就诊的原因。AUB的传统管理包括给予甲芬那酸，氨甲环酸,或与孕激素或激素宫内注射左炔诺孕酮宫内节育器（LNG-IUS）联合治疗严重或无反应的病例。本研究的目的是研究添加地奥司明以及氨甲环酸和甲芬那酸在减少AUB患者月经失血中的疗效和安全性。
■这是一项前瞻性双盲随机对照试验，其中在月经期间每天一次给予900毫克地奥司明，同时给予500毫克氨甲环酸和250毫克甲芬那酸（I-92组患者），或仅在月经期间使用氨甲环酸和甲芬那酸（II-92组患者）。
■平均年龄，奇偶校验，身体质量指数,两组的社会经济地位相似。那是35.68年，而36.78年，分别为2.2对2.3、23.68kg/m2对24.62kg/m2。治疗前的平均出血天数分别为6.8和6.6（P=0.33），治疗后分别为3.5和5.2（P=0.02）。与治疗前相比，两组均显着降低（I组P=0.021，在II组中为0.027），但在I组中降低更大（P=0.02）。治疗前失血量为385ml与390ml（P=0.7），两组均显着降低至68ml与112ml（I组P=0.02，第II组0.03），第I组比第II组减少更多（P=0.01）。研究开始时，I组和II组的平均血红蛋白分别为8.4和8.5g/dl（P=0.02），治疗后两组均显着增加至I组和II组的10.9和9.8g/dl（P=0.012在I组中，第II组的0.011），第I组比第II组的增加更多（P=0.03）。图示血液评估图评分为治疗前398与406（P=0.35），并显着降低至86.5和110.5（I组P=0.001，II组中为0.001），I组比II组降低更多（P=0.01）。两种治疗方法的痛经均显着减少，两组无差异。各种不良反应，如恶心，呕吐,腹痛,腹泻,便秘,和头痛在两组中是相等的。
■两组的地奥司明与氨甲环酸和甲芬那酸（组I）和氨甲环酸和甲芬那酸（组II）均有效减少月经失血，月经天数和痛经的效果更多，通过添加地奥司明。两组的不良反应相同。
■这是一项前瞻性双盲随机对照试验，其中在月经期间每天一次给予900毫克地奥司明，同时给予500毫克氨甲环酸和250毫克甲芬那酸（I-92组患者），或仅在月经期间使用氨甲环酸和甲芬那酸（II-92组患者）。
■平均年龄，奇偶校验，身体质量指数,两组的社会经济地位相似。那是35.68年，而36.78年，分别为2.2对2.3、23.68kg/m2对24.62kg/m2。治疗前的平均出血天数分别为6.8和6.6（P=0.33），治疗后分别为3.5和5.2（P=0.02）。与治疗前相比，两组均显着降低（I组P=0.021，在II组中为0.027），但在I组中降低更大（P=0.02）。治疗前失血量为385ml与390ml（P=0.7），两组均显着降低至68ml与112ml（I组P=0.02，第II组0.03），第I组比第II组减少更多（P=0.01）。研究开始时，I组和II组的平均血红蛋白分别为8.4和8.5g/dl（P=0.02），治疗后两组均显着增加至I组和II组的10.9和9.8g/dl（P=0.012在I组中，第II组的0.011），第I组比第II组的增加更多（P=0.03）。图示血液评估图评分为治疗前398与406（P=0.35），并显着降低至86.5和110.5（I组P=0.001，II组中为0.001），I组比II组降低更多（P=0.01）。两种治疗方法的痛经均显着减少，两组无差异。各种不良反应，如恶心，呕吐,腹痛,腹泻,便秘,和头痛在两组中是相等的。
■两组的地奥司明与氨甲环酸和甲芬那酸（组I）和氨甲环酸和甲芬那酸（组II）均有效减少月经失血，月经天数和痛经的效果更多，通过添加地奥司明。两组的不良反应相同。
